Vireo Growth (VREOF) has received federal Drug Enforcement Administration registrations for all 41 of its state-licensed medical cannabis dispensaries in Florida. The registrations are among the initial federal registrations issued to qualifying state-licensed medical marijuana dispensaries under the Schedule III framework established by the DEA’s April 2026 final rule.
The registrations cover Vireo’s entire Florida dispensary footprint. The company described Florida as one of its key markets and welcomed continued progress toward a federal regulatory framework for state-licensed cannabis operators.
Vireo Growth (VREOF) will host a conference call on November 10, 2026, to discuss third-quarter financial results and business strategy. The call begins at 8:00 a.m. ET and covers the quarter ended September 30, 2026. Results will be released before the call. Management will hold a question-and-answer period, and a live audio webcast will be available through the company's Investor Relations website.
Vireo Growth (VREOF) announced that its property borrowers entered into US$60 million in financing for New York and Florida facilities. Approximately US$49 million of proceeds are being used to refinance existing senior debt connected to the Johnstown facility purchase option, and approximately US$11 million to finance acquisition of the Palatka facility supporting Green Dragon operations.
The loan bears 8.5% annual interest and matures on April 2, 2034. Security includes first-priority mortgages on both properties, pledged subsidiary membership interests and substantially all personal property of the borrowers and other loan parties. In connection with the Palatka acquisition, the existing Rainbow lease will be terminated and a new lease executed with Vireo affiliate Green Dragon Florida.
Vireo Growth (VREOF) entered a three-year put/call agreement with Battle Green Holdings SR to acquire a loan with US$18,096,028 principal.
The loan is evidenced by a note issued by BG Ohio SPV. Battle Green may require Vireo to purchase it with subordinate voting shares priced at US$19.50 each; Vireo may elect to purchase it with shares priced at US$18.60. Exercising either right would result in a maximum of 972,905 shares based on principal. If neither right is exercised by maturity, Vireo will acquire the note using shares priced at their trailing 30-day volume weighted average price, subject to CSE pricing minimums. Additional shares may cover accrued interest, although Vireo may pay interest in cash. No shares will be issued until a purchase right is exercised and all applicable conditions are satisfied.
Vireo Growth (VREOD) has closed its previously announced indirect acquisition of M3 Wellness, a dispensary in Hawthorne, Nevada, under an asset purchase agreement dated June 5, 2026.
The total transaction consideration was $500,000, with $290,000 paid in cash at closing. The remaining $210,000 was satisfied through the issuance of 13,888 subordinate voting shares of Vireo at a deemed issue price of $15.12 per share.
Vireo Growth (VREOD, VREOF) will issue 462,963 subordinate voting shares to SHWZ Altmore, LLC and Altmore Debt I, LP under a confidential settlement agreement related to Vireo’s acquisition of certain secured obligations and related liens held by Altmore.
The shares, defined as Settlement Shares, are being issued as consideration for the assigned interest pursuant to an assignment and assumption agreement. The Settlement Shares will be subject to a six‑month lock‑up period from issuance and resale restrictions, during which holders may not transfer the shares without Vireo’s prior written consent. All other settlement terms remain confidential.
Vireo Growth (VREOD, VREOF) plans to attend the ATB Cormark Capital Markets 2026 Life Sciences Fall Institutional Investor Conference on September 9, 2026, in New York City.
Chief Financial Officer Tyson Macdonald will hold one-on-one meetings with investors. The company’s current Q2 2026 investor presentation is available on its investor relations website.
Vireo Growth (CSE: VREO, OTCQX: VREOF) has completed its previously announced acquisition of all issued and outstanding shares of C21 Investments (CSE: CXXI, OTCQX: CXXIF) via a court-approved plan of arrangement under British Columbia law. C21 shareholders received 0.023052 Vireo subordinate voting shares for each C21 common share, resulting in the issuance of an aggregate 2,766,409 Vireo shares.
According to Vireo, the deal adds three Silver State Relief dispensaries and about 104,000 sq. ft. of cultivation and production, expanding its Nevada footprint to roughly 14 dispensaries and 159,000 sq. ft. of cultivation and manufacturing. C21 common shares are expected to be delisted from the CSE and OTCQX, and C21 plans to cease being a reporting issuer and deregister its shares in due course.
Vireo Growth (CSE: VREO, OTCQX: VREOF) received board authorization for a normal course issuer bid share buyback program starting August 17, 2026. The company may repurchase up to 2,426,872 subordinate voting shares on the Canadian Securities Exchange, with any repurchased shares to be cancelled.
As of August 13, 2026, Vireo Growth had 48,517,509 subordinate voting shares and 7,718 multiple voting shares outstanding, with the latter convertible into 771,800 subordinate voting shares. Purchases will be executed by Haywood Securities under an automatic repurchase plan that allows buying at prices up to US$18.75 per share, within preset parameters. The program runs until August 17, 2027 and may be amended, suspended or terminated; the company is not obligated to purchase any shares.
Vireo Growth (CSE: VREO, OTCQX: VREOF) reported Q2 2026 GAAP revenue of $209.3 million, up 335% year-over-year, with pro forma revenue of $254.9 million assuming recent acquisitions. GAAP gross profit rose to $95.3 million with a 45.5% margin, while non-GAAP adjusted EBITDA reached $41.5 million (19.8% margin).
Growth was driven by closing the Hawthorne, Eaze and Bridgewell deals and announcing acquisitions of FLUENT and C21, plus multiple post-quarter transactions including PharmaCann assets, Cannabist assets, four Ohio deals, and a merger agreement with Planet 13. Vireo ended Q2 with $122.7 million in cash, a new $65–105 million asset-based revolver, and approximately 54.4 million subordinate voting shares outstanding on a treasury-method basis.